An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

NCT ID: NCT02561078


Title
Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial
Purpose
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.
Details
Conditions
Type 2 Diabetes Mellitus
Keywords
insulin pumps, concentrated insulin, OmniPod
Source
Eli Lilly and Company
Sponsors
Eli Lilly and Company, Insulet Corporation
Status
Active, not recruiting
Acronym
VIVID
Last Updated
15 Jan 2017
URL
Official Link
Locations
Puerto Rico, United States